Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally

In their correspondence, G uglielmetti et al. [1] emphasise the importance of improved access to rifapentine globally, both for the treatment of tuberculosis (TB) disease and as part of TB preventive treatment (TPT) regimens. They also highlight some of the major problems with access to this medicin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal 2022-08, Vol.60 (2), p.2201227
Hauptverfasser: Masini, Tiziana, Kanchar, Avinash, Mirzayev, Fuad, Viney, Kerri, Yedilbayev, Askar, Zignol, Matteo, Falzon, Dennis
Format: Artikel
Sprache:eng
Schlagworte:
Agora
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 2201227
container_title The European respiratory journal
container_volume 60
creator Masini, Tiziana
Kanchar, Avinash
Mirzayev, Fuad
Viney, Kerri
Yedilbayev, Askar
Zignol, Matteo
Falzon, Dennis
description In their correspondence, G uglielmetti et al. [1] emphasise the importance of improved access to rifapentine globally, both for the treatment of tuberculosis (TB) disease and as part of TB preventive treatment (TPT) regimens. They also highlight some of the major problems with access to this medicine, especially in the European Union (EU), foremost amongst which being the absence of market authorisation of rifapentine in the EU. In this letter we highlight key actions taken by the World Health Organization (WHO) to address important barriers to the implementation of recommendations on rifapentine. Global access to rifapentine is essential to implement the latest WHO recommendations on treatment of TB infection and disease. Measures to increase access to rifapentine include strengthening regulatory reliance practices. https://bit.ly/3xNDwID
doi_str_mv 10.1183/13993003.01227-2022
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9403394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2684099918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-831e3761ad785aa2439aa54ab1bbf58851fb6a7c3cadcb4b4cdbde410842ae1b3</originalsourceid><addsrcrecordid>eNpVkU2LFDEQhoMo7uzoL_CSo5dek1T6IxdBFleFBS-Kx1BJqsdIpjObdC8M-OPtdldh61LwVtVbVTyMvZHiSsoB3kkwBoSAKyGV6hsllHrGdpvabPJzthNGQCMNdBfsstZfQshOg3zJLqDt1-jUjv3-EQMVjt5TrXzO_G7BFOdzg7UuhQIvccQTTXOcqHFYN4UO8UhT5bHyiSis0jq3OSQqOBOfF0fFLynXteNU6H4bzxPHKXCPhfghZYcpnV-xFyOmSq8f8559v_n47fpzc_v105frD7eNh0HNzQCSoO8khn5oEZUGg9hqdNK5sR2GVo6uw96Dx-CddtoHF0hLMWiFJB3s2fsH39PijhT8ek_BZE8lHrGcbcZon1am-NMe8r01WgAYvRq8fTQo-W6hOttjrOu_CSfKS7WqG7QwxqxY9gweWn3JtRYa_6-Rwm7c7D9u9i83u3GDP3iYjik</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2684099918</pqid></control><display><type>article</type><title>Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Masini, Tiziana ; Kanchar, Avinash ; Mirzayev, Fuad ; Viney, Kerri ; Yedilbayev, Askar ; Zignol, Matteo ; Falzon, Dennis</creator><creatorcontrib>Masini, Tiziana ; Kanchar, Avinash ; Mirzayev, Fuad ; Viney, Kerri ; Yedilbayev, Askar ; Zignol, Matteo ; Falzon, Dennis</creatorcontrib><description>In their correspondence, G uglielmetti et al. [1] emphasise the importance of improved access to rifapentine globally, both for the treatment of tuberculosis (TB) disease and as part of TB preventive treatment (TPT) regimens. They also highlight some of the major problems with access to this medicine, especially in the European Union (EU), foremost amongst which being the absence of market authorisation of rifapentine in the EU. In this letter we highlight key actions taken by the World Health Organization (WHO) to address important barriers to the implementation of recommendations on rifapentine. Global access to rifapentine is essential to implement the latest WHO recommendations on treatment of TB infection and disease. Measures to increase access to rifapentine include strengthening regulatory reliance practices. https://bit.ly/3xNDwID</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.01227-2022</identifier><identifier>PMID: 35777762</identifier><language>eng</language><publisher>European Respiratory Society</publisher><subject>Agora</subject><ispartof>The European respiratory journal, 2022-08, Vol.60 (2), p.2201227</ispartof><rights>Copyright ©The authors 2022. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-831e3761ad785aa2439aa54ab1bbf58851fb6a7c3cadcb4b4cdbde410842ae1b3</citedby><cites>FETCH-LOGICAL-c382t-831e3761ad785aa2439aa54ab1bbf58851fb6a7c3cadcb4b4cdbde410842ae1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Masini, Tiziana</creatorcontrib><creatorcontrib>Kanchar, Avinash</creatorcontrib><creatorcontrib>Mirzayev, Fuad</creatorcontrib><creatorcontrib>Viney, Kerri</creatorcontrib><creatorcontrib>Yedilbayev, Askar</creatorcontrib><creatorcontrib>Zignol, Matteo</creatorcontrib><creatorcontrib>Falzon, Dennis</creatorcontrib><title>Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally</title><title>The European respiratory journal</title><description>In their correspondence, G uglielmetti et al. [1] emphasise the importance of improved access to rifapentine globally, both for the treatment of tuberculosis (TB) disease and as part of TB preventive treatment (TPT) regimens. They also highlight some of the major problems with access to this medicine, especially in the European Union (EU), foremost amongst which being the absence of market authorisation of rifapentine in the EU. In this letter we highlight key actions taken by the World Health Organization (WHO) to address important barriers to the implementation of recommendations on rifapentine. Global access to rifapentine is essential to implement the latest WHO recommendations on treatment of TB infection and disease. Measures to increase access to rifapentine include strengthening regulatory reliance practices. https://bit.ly/3xNDwID</description><subject>Agora</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkU2LFDEQhoMo7uzoL_CSo5dek1T6IxdBFleFBS-Kx1BJqsdIpjObdC8M-OPtdldh61LwVtVbVTyMvZHiSsoB3kkwBoSAKyGV6hsllHrGdpvabPJzthNGQCMNdBfsstZfQshOg3zJLqDt1-jUjv3-EQMVjt5TrXzO_G7BFOdzg7UuhQIvccQTTXOcqHFYN4UO8UhT5bHyiSis0jq3OSQqOBOfF0fFLynXteNU6H4bzxPHKXCPhfghZYcpnV-xFyOmSq8f8559v_n47fpzc_v105frD7eNh0HNzQCSoO8khn5oEZUGg9hqdNK5sR2GVo6uw96Dx-CddtoHF0hLMWiFJB3s2fsH39PijhT8ek_BZE8lHrGcbcZon1am-NMe8r01WgAYvRq8fTQo-W6hOttjrOu_CSfKS7WqG7QwxqxY9gweWn3JtRYa_6-Rwm7c7D9u9i83u3GDP3iYjik</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Masini, Tiziana</creator><creator>Kanchar, Avinash</creator><creator>Mirzayev, Fuad</creator><creator>Viney, Kerri</creator><creator>Yedilbayev, Askar</creator><creator>Zignol, Matteo</creator><creator>Falzon, Dennis</creator><general>European Respiratory Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220801</creationdate><title>Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally</title><author>Masini, Tiziana ; Kanchar, Avinash ; Mirzayev, Fuad ; Viney, Kerri ; Yedilbayev, Askar ; Zignol, Matteo ; Falzon, Dennis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-831e3761ad785aa2439aa54ab1bbf58851fb6a7c3cadcb4b4cdbde410842ae1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Agora</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masini, Tiziana</creatorcontrib><creatorcontrib>Kanchar, Avinash</creatorcontrib><creatorcontrib>Mirzayev, Fuad</creatorcontrib><creatorcontrib>Viney, Kerri</creatorcontrib><creatorcontrib>Yedilbayev, Askar</creatorcontrib><creatorcontrib>Zignol, Matteo</creatorcontrib><creatorcontrib>Falzon, Dennis</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masini, Tiziana</au><au>Kanchar, Avinash</au><au>Mirzayev, Fuad</au><au>Viney, Kerri</au><au>Yedilbayev, Askar</au><au>Zignol, Matteo</au><au>Falzon, Dennis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally</atitle><jtitle>The European respiratory journal</jtitle><date>2022-08-01</date><risdate>2022</risdate><volume>60</volume><issue>2</issue><spage>2201227</spage><pages>2201227-</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>In their correspondence, G uglielmetti et al. [1] emphasise the importance of improved access to rifapentine globally, both for the treatment of tuberculosis (TB) disease and as part of TB preventive treatment (TPT) regimens. They also highlight some of the major problems with access to this medicine, especially in the European Union (EU), foremost amongst which being the absence of market authorisation of rifapentine in the EU. In this letter we highlight key actions taken by the World Health Organization (WHO) to address important barriers to the implementation of recommendations on rifapentine. Global access to rifapentine is essential to implement the latest WHO recommendations on treatment of TB infection and disease. Measures to increase access to rifapentine include strengthening regulatory reliance practices. https://bit.ly/3xNDwID</abstract><pub>European Respiratory Society</pub><pmid>35777762</pmid><doi>10.1183/13993003.01227-2022</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0903-1936
ispartof The European respiratory journal, 2022-08, Vol.60 (2), p.2201227
issn 0903-1936
1399-3003
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9403394
source EZB-FREE-00999 freely available EZB journals
subjects Agora
title Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A37%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Wider%20access%20to%20quality-assured%20rifapentine-based%20regimens%20is%20needed%20to%20accelerate%20tuberculosis%20prevention%20and%20care%20globally&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Masini,%20Tiziana&rft.date=2022-08-01&rft.volume=60&rft.issue=2&rft.spage=2201227&rft.pages=2201227-&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.01227-2022&rft_dat=%3Cproquest_pubme%3E2684099918%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2684099918&rft_id=info:pmid/35777762&rfr_iscdi=true